Page last updated: 2024-12-06

dapoxetine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID71353
CHEMBL ID2110900
CHEBI ID135962
SCHEMBL ID34479
MeSH IDM0215302

Synonyms (49)

Synonym
n,n-dimethyl-alpha-[2-(1-naphthalenyloxy)ethyl]-benzenemethanamine
AB01274725-01
ly-210448
dapoxetine ,
ly 210448
dapoxetinum [inn-latin]
benzenemethanamine, n,n-dimethyl-alpha-(2-(1-naphthalenyloxy)ethyl)-, (+)-
dapoxetina [inn-spanish]
dapoxetine [inn]
ly210448
CHEBI:135962
(1s)-n,n-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine
A804264
(s-(+)-n,n-dimethyl-a-[2-(naphthalenyloxy)ethyl]benzenemethanamine hydrochloride;d-dapoxetine hydrochloride
119356-77-3
dapoxetin
(s)-n,n-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine
dapoxetinum
dapoxetina
unii-gb2433a4m3
gb2433a4m3 ,
NCGC00253658-02
AKOS015895183
gtpl7901
DB04884
SCHEMBL34479
cas-119356-77-3
NCGC00253658-01
dtxsid0057627 ,
tox21_113784
dtxcid1031416
kutub
dapoxetine [mart.]
dapoxetine [mi]
dapoxetine [who-dd]
(+)-(s)-n,n-dimethyl-.alpha.-(2-(1-naphthyloxy)ethyl)benzylamine
benzenemethanamine, n,n-dimethyl-.alpha.-(2-(1-naphthalenyloxy)ethyl)-
USRHYDPUVLEVMC-FQEVSTJZSA-N
CHEMBL2110900
AC-22603
AB01274725_02
AS-72866
dimethyl[(1s)-3-(naphthalen-1-yloxy)-1-phenylpropyl]amine
dapoxetine (free base)
Q424965
EX-A4045
s-(+)-n,n-dimethyl-a-[2-(naphthalenyloxy)ethyl]benzenemethanamine
benzenemethanamine, n,n-dimethyl-alpha-[2-(1-naphthalenyloxy)ethyl]-, (alphas)-
HY-B0304

Research Excerpts

Overview

Dapoxetine (DAP) is a serotonin-norepinephrine reuptake inhibitor, and Tadalafil (TAD) is an phosphodiesterase type-5 inhibitor. It is the first drug approved for the on-demand treatment of premature ejaculation (PE)

ExcerptReferenceRelevance
"Dapoxetine is a novel and effective PE drug on the Russian market."( [The evidence for the efficiency and safety of dapoxetine in treating premature ejaculation].
Akhvlediani, ND; Matyukhov, IP, 2017
)
1.43
"Dapoxetine (DAP) is a serotonin-norepinephrine reuptake inhibitor, and Tadalafil (TAD) is a phosphodiesterase type-5 inhibitor. "( Linear Support Vector Regression and Partial Least-Squares for Determination of Dapoxetine Hydrochloride and Tadalafil in Binary Pharmaceutical Mixtures.
Abdelhamid, NS; Anwar, BH; Magdy, MA; Naguib, IA, 2020
)
2.23
"Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). "( Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study.
Aquilina, JW; Arcaniolo, D; Bull, S; Mirone, V; Rivas, D; Verze, P, 2014
)
2.06
"Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). "( Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation.
Akbulut, MF; Gurbuz, ZG; Kirecci, SL; Kucuktopcu, O; Ozgor, F; Ozkuvanci, U; Sarilar, O; Simsek, A,
)
1.87
""Dapoxetine" is a serotonin transport inhibitor indicated for premature ejaculation."( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015
)
1.29
"Dapoxetine hydrochloride is a potent inhibitor of serotonin reuptake transporters. "( Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.
Boeri, L; Capogrosso, P; La Croce, G; Montorsi, F; Russo, A; Salonia, A; Ventimiglia, E, 2016
)
2.19
"Dapoxetine is a short-acting selective serotonin reuptake inhibitor that was recently approved for the on-demand treatment of premature ejaculation (PE)."( Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine.
Aquilina, J; Chang, CP; Kim, SW; McMahon, C; Park, NC; Rivas, D; Rothman, M; Tesfaye, F, 2010
)
2.01
"Dapoxetine is a short-acting selective serotonin reuptake inhibitor developed for the on-demand treatment of premature ejaculation and is approved in some European Union countries, as well as Mexico and Korea, for this indication. "( Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men.
Aquilina, JW; Hsiao, HL; Mudumbi, R; Sharma, O; Thyssen, A; Tianmei, S; Vandebosch, A; Wang, SS, 2010
)
2.13
"Dapoxetine is a potent SSRI, which is administered on demand 1-3 h before planned sexual contact."( Dapoxetine for premature ejaculation.
McMahon, CG, 2010
)
2.52
"Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that has been developed principally for the treatment of PE."( A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation.
Cruickshank, K; Hutchinson, K; Wylie, K, 2012
)
1.39
"Dapoxetine is a serotonin transporter inhibitor currently in development for the treatment of premature ejaculation. "( Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation.
Desai, D; Dresser, MJ; Gupta, S; Lin, D; Modi, NB; Simon, M, 2006
)
2.03

Effects

Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events (AEs) It has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies.

ExcerptReferenceRelevance
"Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events (AEs)."( Comparison of Treatment Emergent Adverse Events in Men With Premature Ejaculation Treated With Dapoxetine and Alternate Oral Treatments: Results From a Large Multinational Observational Trial.
Cai, T; Cucchiara, V; Magno, C; Mirone, V; Palmieri, A; Sabella, F; Verze, P, 2016
)
2.1
"Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events (AEs)."( Comparison of Treatment Emergent Adverse Events in Men With Premature Ejaculation Treated With Dapoxetine and Alternate Oral Treatments: Results From a Large Multinational Observational Trial.
Cai, T; Cucchiara, V; Magno, C; Mirone, V; Palmieri, A; Sabella, F; Verze, P, 2016
)
2.1
"Dapoxetine 30 and 60 mg has been evaluated in five randomized, double-blind, placebo-controlled studies in 6,081 men aged > or = 18 years."( Dapoxetine for premature ejaculation.
McMahon, CG, 2010
)
2.52
"Dapoxetine has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies in various populations worldwide and has recently been approved in several countries."( Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.
Althof, SE; Aquilina, JW; Buvat, J; Kaufman, JM; Levine, SB; McMahon, CG; Porst, H; Rivas, DA; Rothman, M; Tesfaye, F, 2011
)
2.12
"Dapoxetine has moderately better results in terms of IELT and intercourse satisfaction vs placebo without long-term benefit for the patient after it is withdrawn."( Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study.
Safarinejad, MR, 2008
)
1.38

Treatment

Dapoxetine treatment significantly prolonged IELT and improved PEP measures and was generally well tolerated in men with PE in the Asia-Pacific region.

ExcerptReferenceRelevance
"The dapoxetine treatment discontinuation rate was very high."( Reasons and treatment strategy for discontinuation of dapoxetine treatment in premature ejaculation patients in China: A retrospective observational study.
Gao, Q; Geng, Q; Guo, J; Han, Q; Li, C; Wang, F; Zhang, J; Zhong, C, 2022
)
1.45
"Dapoxetine treatment significantly prolonged IELT and improved PEP measures and was generally well tolerated in men with PE in the Asia-Pacific region."( Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine.
Aquilina, J; Chang, CP; Kim, SW; McMahon, C; Park, NC; Rivas, D; Rothman, M; Tesfaye, F, 2010
)
2.01
"Dapoxetine treatment improved significantly mean IELT (arithmetic and geometric) and PRO responses (perceived control over ejaculation, satisfaction with sexual intercourse, ejaculation-related personal distress, and interpersonal difficulty) for acquired and lifelong subtypes, but presence of mild ED diminished PRO responsiveness in both subtypes, particularly those with lifelong PE."( Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials.
Althof, SE; Aquilina, JW; Bull, S; McMahon, CG; Porst, H; Rivas, DA; Sharlip, I; Tesfaye, F, 2010
)
1.27
"Treatment with dapoxetine or alternative care/nondapoxetine."( Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study.
Aquilina, JW; Arcaniolo, D; Bull, S; Mirone, V; Rivas, D; Verze, P, 2014
)
0.97

Toxicity

Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events. Preclinical safety pharmacology studies did not suggest an adverse electrophysiologic or hemodynamic effect with concentrations of dapoxETine up to 2-fold greater than recommended doses.

ExcerptReferenceRelevance
" Mean number of adverse events was 19 for dapoxetine and 7 for placebo (p=0."( Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study.
Safarinejad, MR, 2008
)
0.92
"End points included stopwatch-measured IELT, Premature Ejaculation Profile (PEP) items, clinical global impression of change (CGIC) in PE, and adverse events (AEs)."( Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.
Althof, SE; Aquilina, JW; Buvat, J; Kaufman, JM; Levine, SB; McMahon, CG; Porst, H; Rivas, DA; Rothman, M; Tesfaye, F, 2011
)
0.68
" Preclinical safety pharmacology studies did not suggest an adverse electrophysiologic or hemodynamic effect with concentrations of dapoxetine up to 2-fold greater than recommended doses."( Cardiovascular safety profile of dapoxetine during the premarketing evaluation.
Aquilina, JW; DiBattiste, PM; Kowey, PR; Mudumbi, RV, 2011
)
0.85
" Among studies that provided comprehensive adverse event data, safety and tolerability observations in men with PE were generally similar to those observed in other populations; however, with the exception of dapoxetine, known SSRI-class effects (e."( Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.
McMahon, CG; Porst, H, 2011
)
0.56
"This systematic review of well-controlled clinical trials in PE has demonstrated that while many oral agents, particularly SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of men with PE, few have been evaluated for their effects on the specific elements of the ISSM criteria."( Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.
McMahon, CG; Porst, H, 2011
)
0.57
"Stopwatch-measured average IELT, Clinical Global Impression of Change (CGIC) in PE, Premature Ejaculation Profile (PEP), and treatment-emergent adverse events (TEAEs)."( Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.
Aquilina, JW; Bull, S; Dean, J; Giuliano, F; Hellstrom, WJ; McMahon, CG; Rivas, DA; Sharma, O; Tesfaye, F, 2013
)
0.7
" Most frequent TEAEs were known adverse drug reactions of dapoxetine treatment including nausea (9."( Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.
Aquilina, JW; Bull, S; Dean, J; Giuliano, F; Hellstrom, WJ; McMahon, CG; Rivas, DA; Sharma, O; Tesfaye, F, 2013
)
0.94
"Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events (AEs)."( Comparison of Treatment Emergent Adverse Events in Men With Premature Ejaculation Treated With Dapoxetine and Alternate Oral Treatments: Results From a Large Multinational Observational Trial.
Cai, T; Cucchiara, V; Magno, C; Mirone, V; Palmieri, A; Sabella, F; Verze, P, 2016
)
2.1
" After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients."( [Efficacy and safety of dapoxetine in the treatment of premature ejaculation].
Chen, XY; Qu, YW; Wang, SG, 2016
)
0.74
" The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3."( [Efficacy and safety of dapoxetine in the treatment of premature ejaculation].
Chen, XY; Qu, YW; Wang, SG, 2016
)
0.98
"Dapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions."( [Efficacy and safety of dapoxetine in the treatment of premature ejaculation].
Chen, XY; Qu, YW; Wang, SG, 2016
)
2.18
"The most common adverse events with dapoxetine are nausea, dizziness, somnolence, headache, diarrhoea and insomnia."( Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.
Boeri, L; Capogrosso, P; La Croce, G; Montorsi, F; Russo, A; Salonia, A; Ventimiglia, E, 2016
)
1.02
"Dapoxetine is the only effective and safe available on-label oral treatment for PE, and its use can result in better quality of life for the patient and their sexual partner."( Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.
Boeri, L; Capogrosso, P; La Croce, G; Montorsi, F; Russo, A; Salonia, A; Ventimiglia, E, 2016
)
2.19
" The combined dapoxetine with sildenafil therapy could significantly improve PE patients without ED as compared to paroxetine alone or dapoxetine alone or sildenafil alone with tolerated adverse effects."( Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial.
Abdelhamed, A; Abu El-Hamd, M, 2018
)
1.07
" After 4 and 8 weeks of medication, we recorded and compared the changes in the intravaginal ejaculation latency time (IELT), measures of the PE profile (PEP), and adverse events among the three groups of patients."( [Efficacy and safety of Yimusake Tablets plus dapoxetine hydrochloride in the treatment of premature ejaculation].
Jiao, X; Li, YF; Yan, XQ; Yang, DK, 2016
)
0.69
" Adverse reactions were observed in 2 cases (3."( [Efficacy and safety of Yimusake Tablets plus dapoxetine hydrochloride in the treatment of premature ejaculation].
Jiao, X; Li, YF; Yan, XQ; Yang, DK, 2016
)
0.69
" MATERIAL AND METHODS We performed a meta-analysis of intravaginal ejaculatory latency time (IELT), patient-reported global impression of change (PGIC), perceived control over ejaculation (PCOE), and drug-related adverse effects (AEs)."( Efficacy and Safety of "On-Demand" Dapoxetine in Treatment of Patients with Premature Ejaculation: A Meta-Analysis.
Bai, X; Du, Y; Jiang, Y; Tian, G; Wu, D; Zhang, J; Zhang, N, 2019
)
0.79
" Efficacy endpoints included intravaginal ejaculatory latency times (IELT), personal distress related to ejaculation (PDRE) and treatment-emergent adverse events (TEAEs) was used to evaluate safety."( Efficacy and safety of dapoxetine for premature ejaculation: an updated systematic review and meta-analysis.
Guo, Q; Li, YF; Zhang, YG; Zhao, GJ, 2019
)
0.82
" Therefore, combined therapy involving the Qiaoshao formula and dapoxetine proved to safe as well as effective for treating premature ejaculation while prolonging the perceived intravaginal ejaculation latency time, which significantly improved the overall satisfaction of the patient and likely that of the couple."( Safety and efficacy of traditional Chinese medicine, Qiaoshao formula, combined with dapoxetine in the treatment of premature ejaculation: An open-label, real-life, retrospective multicentre study in Chinese men.
Bin, B; Cai, J; Colonnello, E; Gao, Q; Geng, Q; Guo, B; Guo, J; Han, Q; Jannini, EA; Wang, F; Xuan, Z; Yan, B; Zhang, C; Zhang, J; Zhang, R; Zhou, Q, 2021
)
1.08
" The adverse events in the high-dose group under fasted and fed states were 37."( Pharmacokinetics and Safety of Dapoxetine Hydrochloride in Healthy Chinese Men: Impact of Dose and High-Fat Meal.
Ju, G; Li, Z; Liu, J; Qiu, W; Yan, K, 2021
)
0.91

Pharmacokinetics

Dapoxetine is being developed as a treatment for premature ejaculation and has demonstrated rapid absorption and elimination in previous pharmacokinetic studies. The aim of study is to develop a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method to investigate the drug interaction.

ExcerptReferenceRelevance
"Potential pharmacokinetic interactions between dapoxetine, a serotonin transporter inhibitor developed for the treatment of premature ejaculation (PE), and the phosphodiesterase-5 inhibitors tadalafil and sildenafil, agents used in the treatment of erectile dysfunction (ED), were investigated in an open-label, randomized, crossover study (n=24 men) comparing dapoxetine 60 mg, dapoxetine 60 mg+tadalafil 20 mg, and dapoxetine 60 mg+sildenafil 100 mg."( Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
Desai, D; Dresser, MJ; Gidwani, S; Modi, NB; Seftel, AD,
)
1.83
"To describe the relationship between the pharmacokinetic and pharmacodynamic properties of dapoxetine, a drug specifically developed for treating premature ejaculation (PE)."( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation.
Andersson, KE; Mulhall, JP; Wyllie, MG, 2006
)
0.81
" The clinical characteristics were then compared with the pharmacokinetic profile, determined from measured plasma drug concentrations."( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation.
Andersson, KE; Mulhall, JP; Wyllie, MG, 2006
)
0.59
"Pharmacodynamic and pharmacokinetic measurements confirm that 'on demand' dapoxetine has a rapid onset of action and is rapidly cleared after sexual intercourse."( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation.
Andersson, KE; Mulhall, JP; Wyllie, MG, 2006
)
0.82
" Its physicochemical and pharmacokinetic properties and its clinical efficacy make dapoxetine suitable for on-demand treatment of PE."( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation.
Andersson, KE; Mulhall, JP; Wyllie, MG, 2006
)
0.81
"Dapoxetine is being developed as a treatment for premature ejaculation and has demonstrated rapid absorption and elimination in previous pharmacokinetic studies."( Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal.
Dresser, MJ; Gidwani, S; Guo, C; Kang, D; Modi, NB; Mulhall, JP; Staehr, P, 2006
)
2.1
" Dapoxetine was eliminated in a biphasic manner with an apparent mean terminal half-life of 14 to 17 hours."( Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men.
Aquilina, JW; Hsiao, HL; Mudumbi, R; Sharma, O; Thyssen, A; Tianmei, S; Vandebosch, A; Wang, SS, 2010
)
1.59
" The aim of the study reported here was to investigate the pharmacokinetic drug interaction between udenafil and dapoxetine in healthy male subjects."( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015
)
0.88
" Pharmacokinetic parameters were obtained by non-compartmental analysis."( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015
)
0.67
"Udenafil was found to have no clinically significant pharmacokinetic interactions with dapoxetine."( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015
)
0.89
"The aim of study is to develop a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method to investigate the pharmacokinetic interaction of Epimedium extract on the dapoxetine in rats."( Herb-drug interaction of Epimedium extract on the pharmacokinetic of dapoxetine in rats.
Chiu, AW; Ho, JK; Hsueh, TY; Lin, CH; Lin, LC; Tsai, TH, 2016
)
0.86
" Plasma concentration of dapoxetine was determined by high-performance liquid chromatography-tandem mass spectrometry, and the pharmacokinetic parameters were calculated using noncompartmental analysis."( Pharmacokinetics and Safety of Dapoxetine Hydrochloride in Healthy Chinese Men: Impact of Dose and High-Fat Meal.
Ju, G; Li, Z; Liu, J; Qiu, W; Yan, K, 2021
)
1.21

Compound-Compound Interactions

To evaluate the efficacy and safety of tamsulosin combined with dapoxetine in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) that is complicated by premature ejaculation.

ExcerptReferenceRelevance
"To evaluate the overall treatment benefits of premature ejaculation desensitisation therapy combined with 30 mg dapoxetine hydrochloride treatment on patients with primary premature ejaculation (PPE)."( Effect of premature ejaculation desensitisation therapy combined with dapoxetine hydrochloride on the treatment of primary premature ejaculation.
Fu, M; Hu, Y; Peng, X, 2019
)
0.96
"To evaluate the efficacy and safety of tamsulosin combined with dapoxetine in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) that is complicated by premature ejaculation (PE), a total of 251 CP/CPPS patients with PE were recruited from nine hospitals across China and were randomly divided into two groups: one received tamsulosin as a control, and the other received a combination therapy of tamsulosin and dapoxetine."( Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation.
Ji, Z; Li, Z; Liang, C; Song, W; Tian, R; Wang, Z; Xia, S; Zhang, L; Zhao, J; Zhao, L, 2019
)
1.01
"To evaluate the safety and efficacy of Chinese medicine, Qiaoshao formula combined with dapoxetine was used for the treatment of premature ejaculation in a real-life setting."( Safety and efficacy of traditional Chinese medicine, Qiaoshao formula, combined with dapoxetine in the treatment of premature ejaculation: An open-label, real-life, retrospective multicentre study in Chinese men.
Bin, B; Cai, J; Colonnello, E; Gao, Q; Geng, Q; Guo, B; Guo, J; Han, Q; Jannini, EA; Wang, F; Xuan, Z; Yan, B; Zhang, C; Zhang, J; Zhang, R; Zhou, Q, 2021
)
1.07
"To observe the clinical effect of priligy (dapoxetine hydrochloride) combined with behavioral therapy and psychological counseling in the treatment of primary premature ejaculation (PPE)."( [Priligy combined with behavioral therapy and psychological counseling for primary premature ejaculation].
Cai, DY; Guo, KM; Li, FB; Wang, HL; Wu, J; Xu, SQ; Yang, YP, 2020
)
0.82
"A total of 202 PPE patients diagnosed from 2017 to 2018 were randomized into a control (n = 100) and an experimental group (n = 102), the former treated with oral priligy at 30 mg 1-3 hours before anticipated sexual activity, and the latter by the same medication combined with 30-minute behavioral therapy and psychological counseling once a month for two times."( [Priligy combined with behavioral therapy and psychological counseling for primary premature ejaculation].
Cai, DY; Guo, KM; Li, FB; Wang, HL; Wu, J; Xu, SQ; Yang, YP, 2020
)
0.56
"Priligy combined with behavioral therapy and psychological counseling is more effective than priligy alone in improving the sexual function of PPE patients, raise their interest in sexual life and increase the intimacy between the partners, and can even achieve clinical cure in some patients."( [Priligy combined with behavioral therapy and psychological counseling for primary premature ejaculation].
Cai, DY; Guo, KM; Li, FB; Wang, HL; Wu, J; Xu, SQ; Yang, YP, 2020
)
0.56

Bioavailability

Dapoxetine (DPX), a recently approved drug for the treatment of PE, suffers from low bioavailability with large variability that ranges from 15-76% (mean 42%) after oral administration.

ExcerptReferenceRelevance
" The oral bioavailability of dapoxetine was about 75% in rats."( Herb-drug interaction of Epimedium extract on the pharmacokinetic of dapoxetine in rats.
Chiu, AW; Ho, JK; Hsueh, TY; Lin, CH; Lin, LC; Tsai, TH, 2016
)
0.96
"Dapoxetine (D) suffers from poor oral bioavailability (42%) due to extensive first pass metabolism."( Novel instantly-soluble transmucosal matrix (ISTM) using dual mechanism solubilizer for sublingual and nasal delivery of dapoxetine hydrochloride: In-vitro/in-vivo evaluation.
Basalious, EB; El-Nabarawi, MA; Fouad, SA; Shamma, RN; Tayel, SA, 2016
)
2.08
"Dapoxetine (D) suffers from poor oral bioavailability (42%) due to extensive metabolism in the liver."( Novel instantly-dispersible nanocarrier powder system (IDNPs) for intranasal delivery of dapoxetine hydrochloride: in-vitro optimization, ex-vivo permeation studies, and in-vivo evaluation.
Basalious, EB; El-Nabarawi, MM; Fouad, SA; Shamma, RN; Tayel, SA, 2018
)
2.15
" DPX is characterized by relatively low bioavailability (42%) and short half-life (1."( Self-assembled biodegradable polymeric micelles to improve dapoxetine delivery across the blood-brain barrier.
Abourehab, MA; Ahmed, OA; Almalki, WH; Balata, GF, 2018
)
0.72
"DPX formulations in the form of PMs improved bioavailability and efficacy across the BBB."( Self-assembled biodegradable polymeric micelles to improve dapoxetine delivery across the blood-brain barrier.
Abourehab, MA; Ahmed, OA; Almalki, WH; Balata, GF, 2018
)
0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Dapoxetine (DPX), a recently approved drug for the treatment of PE, suffers from low bioavailability with large variability that ranges from 15-76% (mean 42%) after oral administration."( Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation.
Ahmed, OA; El-Say, KM; Mohamed, AI; Omar, AM; Safo, MK, 2019
)
1.65
"The clinical findings suggest 194% enhancement of relative bioavailability of the optimized DPX-loaded NPs, potentially leading to a decrease in therapeutic dose and associated side effects in the treatment of PE."( Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation.
Ahmed, OA; El-Say, KM; Mohamed, AI; Omar, AM; Safo, MK, 2019
)
0.74

Dosage Studied

The presented study is using previously analyzed pharmaceutical mixtures of Dapoxetine Hydrochloride (DAP) and Tadalafil (TAD) as a case study. Phase I clinical pharmacology studies demonstrated that dap Oxetine did not prolong the QT/QTc interval and had neither clinically sign up. In the 3 ethnic groups, dapOxetine was rapidly absorbed following oral administration.

ExcerptRelevanceReference
" Most tissues had returned to background radioactive levels 72 h after dosing but persistent concentrations of radiocarbon were present in the preputial gland and liver one week after the single dose of 14C-dapoxetine."( Disposition of 14C-dapoxetine in rats: complementary experiments with whole-body autoradiographic and tissue dissection techniques.
Bernstein, JR; Franklin, RB; Manzione, BM; Pohland, RC, 1994
)
0.8
" The process of ejaculation is under central control, and serotonin (5-HT) is a key mediator; therefore, SSRIs and tricyclic antidepressants, including paroxetine, sertraline and clomipramine, are commonly used with chronic daily dosing in the treatment of PE."( Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation.
Hellstrom, WJ; Patel, K, 2009
)
0.35
" In the 3 ethnic groups, dapoxetine was rapidly absorbed following oral administration, with peak plasma concentrations evident approximately 1 hour after dosing, independent of dose, dosing frequency (single or multiple dosing), or ethnicity."( Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men.
Aquilina, JW; Hsiao, HL; Mudumbi, R; Sharma, O; Thyssen, A; Tianmei, S; Vandebosch, A; Wang, SS, 2010
)
0.99
" Phase I clinical pharmacology studies demonstrated that dapoxetine did not prolong the QT/QTc interval and had neither clinically significant electrocardiographic effects nor evidence of delayed repolarization or conduction effects, with dosing up to 4-fold greater than the maximum recommended dosage."( Cardiovascular safety profile of dapoxetine during the premarketing evaluation.
Aquilina, JW; DiBattiste, PM; Kowey, PR; Mudumbi, RV, 2011
)
0.9
"We compared on-demand dosing of dapoxetine alone and combined with mirodenafil in subjects with lifelong PE and without erectile dysfunction (ED)."( Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study.
Cho, JS; Cho, ST; Lee, SH; Lee, SK; Lee, WK; Lee, YS; Oh, CY; Yang, DY; Yoo, C, 2013
)
0.94
"Orally disintegrating tablet (ODT) is a user friendly and convenient dosage form."( Investigation on the effect of polymer and starch on the tablet properties of lyophilized orally disintegrating tablet.
Liew, KB; Peh, KK, 2021
)
0.62
" Therefore, a novel, accurate, specific and sensitive reversed-phase high performance liquid chromatographic method with fluorescence detection was developed and validated for their separation and quantitation in dosage form and human plasma using avanafil as an internal standard (IS)."( A novel liquid chromatographic method with fluorescence detection for quantitation of tadalafil and dapoxetine hydrochloride in pharmaceutical dosage form and human plasma.
Ahmed Emad, el G; Amira, K; Maha, H; Mohamed, A, 2015
)
0.63
" The two models were applied on the dosage forms and statistically compared with the published HPLC method with no significant difference regarding accuracy and precision."( Linear Support Vector Regression and Partial Least-Squares for Determination of Dapoxetine Hydrochloride and Tadalafil in Binary Pharmaceutical Mixtures.
Abdelhamid, NS; Anwar, BH; Magdy, MA; Naguib, IA, 2020
)
0.79
" The presented study is using previously analyzed pharmaceutical mixtures of Dapoxetine Hydrochloride (DAP) and Tadalafil (TAD) as a case study, whether in pure forms or in dosage form, where the study uses two datasets for analysis, the first aims to include COA and the second dataset avoids it, then a statistical comparison is conducted for training sets, test sets and dosage form datasets to see how far COA may interfere with analysis results."( Ultraviolet cutoff area and predictive ability of partial least squares regression method: A pharmaceutical case study.
Abdallah, FF; Naguib, IA, 2020
)
0.79
" Based on the different effects of magnitude of the three dosing regimens, we recommend a stepwise approach, starting with 30 mg on demand, then 60 mg on demand and finally 60 mg dapoxetine daily."( Efficacy and safety of dapoxetine for premature ejaculation: an updated systematic review and meta-analysis.
Guo, Q; Li, YF; Zhang, YG; Zhao, GJ, 2019
)
1.02
" Eventually, the procedure was utilized in the dosage form assay and extended to include biological plasma analyses, with good percentage recuperation."( One-pot micellar augmented native fluorescence for facile fluorimetric assay of dapoxetine hydrochloride in biological plasma and tablets.
Abu-Hassan, AA; Ali, R; Derayea, SM, 2020
)
0.79
"We suggested six simple, precise, and sensitive spectrophotometric methods based on mathematical filtration techniques and ratio spectra manipulations to resolve the spectra of DAP and SIL in their bulk and combined pharmaceutical dosage form and estimate the relevant individual concentrations."( Spectral analysis of severely overlapping spectra based on newly developed mathematical filtration techniques and ratio spectra manipulations: An application to the concurrent determination of dapoxetine and sildenafil in combined dosage form.
Abd El-Hay, SS; Attala, K; Eissa, MS; El-Henawee, MM, 2021
)
0.81
"We determined the performance of the suggested methods for estimating DAP and SIL in their laboratory mixtures and their combined pharmaceutical dosage form."( Spectral analysis of severely overlapping spectra based on newly developed mathematical filtration techniques and ratio spectra manipulations: An application to the concurrent determination of dapoxetine and sildenafil in combined dosage form.
Abd El-Hay, SS; Attala, K; Eissa, MS; El-Henawee, MM, 2021
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency34.67130.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency21.54510.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346924
Fumarate hydrataseHomo sapiens (human)Potency34.32740.00308.794948.0869AID1347053
SMAD family member 3Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency24.89950.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency26.60320.000221.22318,912.5098AID1259243; AID1259247
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency29.84930.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency10.59090.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.93470.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency24.27930.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.11420.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.01800.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.07120.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency7.49780.005428.02631,258.9301AID1346982
GVesicular stomatitis virusPotency18.40220.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency0.59770.00108.379861.1304AID1645840
polyproteinZika virusPotency34.32740.00308.794948.0869AID1347053
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency10.59010.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency14.95890.023723.228263.5986AID743222
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency33.49150.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency26.832519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency22.61420.057821.109761.2679AID1159526; AID1159528
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.04500.000627.21521,122.0200AID743202; AID743219
Interferon betaHomo sapiens (human)Potency18.40220.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency18.40220.01238.964839.8107AID1645842
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency9.01310.009610.525035.4813AID1479145; AID1479148
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency18.40220.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency18.40220.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (186)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (1.61)18.2507
2000's43 (23.12)29.6817
2010's98 (52.69)24.3611
2020's42 (22.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.82 (24.57)
Research Supply Index5.50 (2.92)
Research Growth Index5.96 (4.65)
Search Engine Demand Index192.20 (26.88)
Search Engine Supply Index2.67 (0.95)

This Compound (82.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials46 (23.35%)5.53%
Reviews42 (21.32%)6.00%
Case Studies1 (0.51%)4.05%
Observational5 (2.54%)0.25%
Other103 (52.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]